RxDoctor Payments Data

Philip Childers, PA

Physician Assistant · Little Rock, ARNPI 1205347390

Payments from drug & device makers

$3,218in general payments, 2019–2025

Across 117 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$708
  • Johnson & Johnson$638
  • Teleflex LLC$531
  • Tolmar, Inc.$285
  • Axonics, Inc.$189
  • Sumitomo Pharma America, Inc.$129
  • plus $738 from 13 others

What the payments were for

  • Travel & lodging$38412%
  • Food & beverage$2,15367%
  • Education$68121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,218 in reported general payments places this provider in the 80th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$743,289
Medicare patients
1,344
Services billed
29,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide37$520,149
ErleadaApalutamide15$215,824
GemtesaVibegron334$187,743
MyrbetriqMirabegron174$88,739
Abiraterone Acetate27$47,664
OrgovyxRelugolix16$41,638
Tamsulosin Hcl1,395$16,920
Testosterone Cypionate219$5,506
Finasteride449$5,067
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst162$3,988
Estradiol50$3,271
Trimethoprim45$2,921
Oxybutynin Chloride ErOxybutynin Chloride213$2,459
Megestrol Acetate62$2,105
Silodosin19$1,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$708$608,888211 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$129$229,382350 claims
Johnson & JohnsonErleada$638$215,82415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →